Drug Trial Radar · NCT07399067
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Feb 6, 2026
Primary completion
Mar 23, 2027
Study completion May 27, 2027
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).
Conditions
- Atopic Dermatitis
Interventions
IBI3002Drug
IBI3002 will be administered subcutaneously at the assigned dose level and dosing interval.
PlaceboDrug
Matched placebo will be administered subcutaneously at the same schedule as IBI3002.
DupilumabDrug
Dupilumab 300mg Q2w, with a loading dose of 600mg, will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16Time frame: Week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
China-japan Friendship Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.